Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Desmopressin acetate
Form:
14 of 14 products shown
11 general benefit · 3 not a benefit
Apo-Desmopressin · DIN 02284030 · 0.1 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Desmopressin · DIN 02284030
Manufacturer: Apotex Inc.; listing date 2007-04-02
Health Canada: Marketed since 2022-04-07 · brand APO-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.1 MG · company Apotex inc · schedule Prescription
Apo-Desmopressin: Formulary list price $0.66 per unit (the source does not state the unit; exact figure $0.6609). What the ministry pays, not the patient.
Ministry pays: $0.6609 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02284030: Apo-Desmopressin
Raw flags: sec3=Y
Item: 682800010; group id 790; item number 1926; lccId None; manufacturer id APX
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $0.6609; ministry $0.6609
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02284030
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76960Interchangeable products
DDAVP · DIN 00824305 · $0.6609
PMS-Desmopressin · DIN 02304368 · $0.6609
Shortage status: resolved shortage (ended March 12, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284030
Shortage record checked October 6, 2026
PMS-Desmopressin · DIN 02304368 · 0.1 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Desmopressin · DIN 02304368
Manufacturer: Pharmascience Inc.; listing date 2010-04-23
Health Canada: Marketed since 2008-01-23 · brand PMS-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE (DESMOPRESSIN ACETATE TRIHYDRATE) 0.1 MG · company Pharmascience inc · schedule Prescription
PMS-Desmopressin: Formulary list price $0.66 per unit (the source does not state the unit; exact figure $0.6609). What the ministry pays, not the patient.
Ministry pays: $0.6609 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02304368: PMS-Desmopressin
Raw flags: sec3=Y
Item: 682800010; group id 790; item number 1926; lccId None; manufacturer id PMS
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $0.6609; ministry $0.6609
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02304368
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78965Interchangeable products
Apo-Desmopressin · DIN 02284030 · $0.6609
DDAVP · DIN 00824305 · $0.6609
Shortage status: discontinued (April 5, 2017, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304368
Shortage record checked October 6, 2026
Apo-Desmopressin · DIN 02284049 · 0.2 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Desmopressin · DIN 02284049
Manufacturer: Apotex Inc.; listing date 2007-04-02
Health Canada: Marketed since 2022-04-07 · brand APO-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.2 MG · company Apotex inc · schedule Prescription
Apo-Desmopressin: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3217). What the ministry pays, not the patient.
Ministry pays: $1.3217 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02284049: Apo-Desmopressin
Raw flags: sec3=Y
Item: 682800011; group id 790; item number 1927; lccId None; manufacturer id APX
Source form: Tab; strength: 0.2mg
Recorded listing: General benefit
Source prices (unrounded): $1.3217; ministry $1.3217
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02284049
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76961Interchangeable products
DDAVP · DIN 00824143 · $1.3217
PMS-Desmopressin · DIN 02304376 · $1.3217
Shortage status: resolved shortage (ended January 30, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284049
Shortage record checked October 6, 2026
PMS-Desmopressin · DIN 02304376 · 0.2 mg · tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Desmopressin · DIN 02304376
Manufacturer: Pharmascience Inc.; listing date 2010-04-23
Health Canada: Marketed since 2021-11-25 · brand PMS-DESMOPRESSIN · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE (DESMOPRESSIN ACETATE TRIHYDRATE) 0.2 MG · company Pharmascience inc · schedule Prescription
PMS-Desmopressin: Formulary list price $1.32 per unit (the source does not state the unit; exact figure $1.3217). What the ministry pays, not the patient.
Ministry pays: $1.3217 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02304376: PMS-Desmopressin
Raw flags: sec3=Y
Item: 682800011; group id 790; item number 1927; lccId None; manufacturer id PMS
Source form: Tab; strength: 0.2mg
Recorded listing: General benefit
Source prices (unrounded): $1.3217; ministry $1.3217
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02304376
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78966Interchangeable products
Apo-Desmopressin · DIN 02284049 · $1.3217
DDAVP · DIN 00824143 · $1.3217
Shortage status: discontinued (June 15, 2020, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304376
Shortage record checked October 6, 2026
Desmopressin Spray · DIN 02242465 · 10 mcg/Metered Dose · Nas Sp-2.5mL Pk
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Desmopressin Spray · DIN 02242465
Manufacturer: A A Pharma Inc.; listing date 2002-07-29
Health Canada: Marketed since 2011-03-10 · brand DESMOPRESSIN SPRAY · ATC H01BA02 DESMOPRESSIN · form Spray (metered-dose) · route Nasal · ingredients DESMOPRESSIN ACETATE 10 MCG/ACT · company Aa pharma inc · schedule Prescription
Desmopressin Spray: Formulary list price $42.17 per unit (the source does not state the unit; exact figure $42.1661). What the ministry pays, not the patient.
Ministry pays: $42.1661 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02242465: Desmopressin Spray
Raw flags: sec3=Y
Item: 682800006; group id 790; item number 1922; lccId None; manufacturer id AAP
Source form: Nas Sp-2.5mL Pk; strength: 10mcg/Metered Dose
Recorded listing: General benefit
Source prices (unrounded): $42.1661; ministry $42.1661
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02242465
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66190Interchangeable products
DDAVP · DIN 00836362 · not recorded
Shortage status: active shortage (reported September 8, 2026, estimated to end October 23, 2026, last updated October 2, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242465
Shortage record checked October 6, 2026
DDAVP Melt · DIN 02284995 · 60 mcg · Orally Disintegrating tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
DDAVP Melt · DIN 02284995
Manufacturer: Ferring Inc.; listing date 2007-06-06
Health Canada: Marketed since 2006-11-02 · brand DDAVP MELT · ATC H01BA02 DESMOPRESSIN · form Tablet (orally-disintegrating) · route Sublingual · ingredients DESMOPRESSIN (DESMOPRESSIN ACETATE) 60 MCG · company Ferring inc · schedule Prescription
DIN 02284995: DDAVP Melt
Raw flags: sec3=Y
Item: 682800026; group id 790; item number 1924; lccId None; manufacturer id FEI
Source form: Orally Disintegrating Tab; strength: 60mcg
Recorded listing: General benefit
Source prices (unrounded): $1.4990; ministry $1.4990
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02284995
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77052
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284995
Shortage record checked October 6, 2026
DDAVP Melt · DIN 02285002 · 120 mcg · Orally Disintegrating tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
DDAVP Melt · DIN 02285002
Manufacturer: Ferring Inc.; listing date 2007-06-06
Health Canada: Marketed since 2006-11-02 · brand DDAVP MELT · ATC H01BA02 DESMOPRESSIN · form Tablet (orally-disintegrating) · route Sublingual · ingredients DESMOPRESSIN (DESMOPRESSIN ACETATE) 120 MCG · company Ferring inc · schedule Prescription
DIN 02285002: DDAVP Melt
Raw flags: sec3=Y
Item: 682800027; group id 790; item number 1925; lccId None; manufacturer id FEI
Source form: Orally Disintegrating Tab; strength: 120mcg
Recorded listing: General benefit
Source prices (unrounded): $2.9990; ministry $2.9990
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285002
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77053
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285002
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Bipazen · DIN 02513579
Manufacturer: KVR Pharmaceuticals; listing date 2021-12-17
Health Canada: Marketed since 2021-10-13 · brand BIPAZEN · ATC H01BA02 DESMOPRESSIN · form Solution · route Intravenous, Subcutaneous, Intramuscular · ingredients DESMOPRESSIN ACETATE 4 MCG/ML · company Kvr pharmaceuticals inc. · schedule Prescription
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02513579).
DIN 02513579: Bipazen
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682800007; group id 790; item number 1920; lccId None; manufacturer id KVR
Source form: Inj Sol-1mL Amp Pk; strength: 4mcg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $9.0000; ministry $9.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02513579
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100269Interchangeable products
DDAVP · DIN 00873993 · not recorded
Shortage status: resolved shortage (ended June 4, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02513579
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 17, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
DDAVP · DIN 00873993
Manufacturer: Ferring Inc.; listing date 2021-12-17
Health Canada: Marketed since 1993-12-31 · brand DDAVP INJ 4MCG/ML · ATC H01BA02 DESMOPRESSIN · form Liquid · route Intravenous, Subcutaneous, Intramuscular · ingredients DESMOPRESSIN ACETATE 4 MCG/ML · company Ferring inc · schedule Prescription
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 00873993).
DIN 00873993: DDAVP
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 682800007; group id 790; item number 1920; lccId None; manufacturer id FEI
Source form: Inj Sol-1mL Amp Pk; strength: 4mcg/mL
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00873993
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13867Interchangeable products
Bipazen · DIN 02513579 · $9.0000
Shortage status: resolved shortage (ended May 12, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00873993
Shortage record checked October 6, 2026
DDAVP · DIN 00402516 · 0.1 mg/mL · Nas Sol-2.5mL Pk
General benefit; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.Discontinued January 29, 2021 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
DDAVP · DIN 00402516
Manufacturer: Ferring Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2021-01-29 · brand DDAVP RHINYLE · ATC H01BA02 DESMOPRESSIN · form Solution · route Nasal · ingredients DESMOPRESSIN ACETATE 0.1 MG/ML · company Ferring inc · schedule Prescription
DIN 00402516: DDAVP
Raw flags: sec3=Y
Item: 682800005; group id 790; item number 1921; lccId None; manufacturer id FEI
Source form: Nas Sol-2.5mL Pk; strength: 0.1mg/mL
Recorded listing: General benefit
Source prices (unrounded): $52.0375; ministry $52.0375
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00402516
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14413
Shortage status: discontinued (January 29, 2021, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00402516
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 29, 2021 — choose a marketed DIN from the same-category list.
DDAVP · DIN 00824305 · 0.1 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.Discontinued May 31, 2022 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
DDAVP · DIN 00824305
Manufacturer: Ferring Inc.; listing date 1997-08-28
Health Canada: Cancelled post market since 2022-05-31 · brand DDAVP TABLETS 0.1MG · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.1 MG · company Ferring inc · schedule Prescription
DIN 00824305: DDAVP
Raw flags: sec3=Y
Item: 682800010; group id 790; item number 1926; lccId None; manufacturer id FEI
Source form: Tab; strength: 0.1mg
Recorded listing: General benefit
Source prices (unrounded): $1.3217; ministry $0.6609
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00824305
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19436Interchangeable products
Apo-Desmopressin · DIN 02284030 · $0.6609
PMS-Desmopressin · DIN 02304368 · $0.6609
Shortage status: discontinued (February 28, 2022, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00824305
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 31, 2022 — choose a marketed DIN from the same-category list.
DDAVP · DIN 00824143 · 0.2 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.Discontinued May 31, 2022 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
DDAVP · DIN 00824143
Manufacturer: Ferring Inc.; listing date 1997-08-28
Health Canada: Cancelled post market since 2022-05-31 · brand DDAVP TABLETS 0.2MG · ATC H01BA02 DESMOPRESSIN · form Tablet · route Oral · ingredients DESMOPRESSIN ACETATE 0.2 MG · company Ferring inc · schedule Prescription
DIN 00824143: DDAVP
Raw flags: sec3=Y
Item: 682800011; group id 790; item number 1927; lccId None; manufacturer id FEI
Source form: Tab; strength: 0.2mg
Recorded listing: General benefit
Source prices (unrounded): $2.6434; ministry $1.3217
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00824143
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19441Interchangeable products
Apo-Desmopressin · DIN 02284049 · $1.3217
PMS-Desmopressin · DIN 02304376 · $1.3217
Shortage status: discontinued (May 31, 2022, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00824143
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 31, 2022 — choose a marketed DIN from the same-category list.
DDAVP Melt · DIN 02285010 · 240 mcg · Orally Disintegrating tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.Discontinued May 31, 2022 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2022-05-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
No interchangeable product listed in the Ontario extract
DDAVP Melt · DIN 02285010
Manufacturer: Ferring Inc.; listing date 2010-06-14
Health Canada: Cancelled post market since 2022-05-31 · brand DDAVP MELT · ATC H01BA02 DESMOPRESSIN · form Tablet (orally-disintegrating) · route Sublingual · ingredients DESMOPRESSIN (DESMOPRESSIN ACETATE) 240 MCG · company Ferring inc · schedule Prescription
DIN 02285010: DDAVP Melt
Raw flags: sec3=Y
Item: 682800028; group id 790; item number 1923; lccId None; manufacturer id FEI
Source form: Orally Disintegrating Tab; strength: 240mcg
Recorded listing: General benefit
Source prices (unrounded): $3.9382; ministry $3.9382
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285010
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77054
Shortage status: discontinued (March 31, 2022, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285010
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since May 31, 2022 — choose a marketed DIN from the same-category list.
DDAVP · DIN 00836362 · 10 mcg/Metered Dose · Nas Sp-2.5mL Pk
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.Discontinued July 17, 2020 · checked November 17, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
DDAVP · DIN 00836362
Manufacturer: Ferring Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2020-07-17 · brand DDAVP SPRAY · ATC H01BA02 DESMOPRESSIN · form Metered-dose aerosol · route Nasal · ingredients DESMOPRESSIN ACETATE 10 MCG/ACT · company Ferring inc · schedule Prescription
DIN 00836362: DDAVP
Raw flags: notABenefit=Y, sec3=Y
Item: 682800006; group id 790; item number 1922; lccId None; manufacturer id FEI
Source form: Nas Sp-2.5mL Pk; strength: 10mcg/Metered Dose
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00836362
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9861Interchangeable products
Desmopressin Spray · DIN 02242465 · $42.1661
Shortage status: discontinued (July 14, 2020, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00836362
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 17, 2020 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:28 Pituitary Agents) and how they are covered
Matched class: 68:28 Pituitary Agents
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: THYROTROPIN ALFA
68:28 Pituitary Agents
INDICATIONS AND CLINICAL USE
DDAVP injection is indicated for prophylaxis of mild hemophilia A and mild von Willebrand’s
disease Type I, and for the treatment of central diabetes insipidus.
Hemophilia A
DDAVP injection is indicated for patients with hemophilia A with Factor VIII levels greater than
5%.
DDAVP will often maintain hemostasis in patients with hemophilia A during surgical
procedures and postoperatively, when administered 45 minutes prior to the scheduled procedure.
DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or
trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding.
In certain clinical situations, it may be justified to try DDAVP in patients with Factor VIII levels
between 2-5%, however, these patients should be carefully monitored.
Von Willebrand’s Disease (Type I)
DDAVP injection is indicated for patients with mild to moderate classic von Willebrand’s
Disease (Type I) with Factor VIII levels greater than 5%.
DDAVP will often maintain hemostasis in surgical procedures and postoperatively when
administered 45 minutes prior to the scheduled procedure.
…
https://pdf.hres.ca/dpd_pm/00044657.PDF
PM date: April 5, 2017
Source product: DDAVP INJ 4MCG/ML; DIN 00873993; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
PMS-Desmopressin · DIN 02304368
Shortage status: discontinued (2017-04-05, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304368
PMS-Desmopressin · DIN 02304376
Shortage status: discontinued (2020-06-15, reported by PHARMASCIENCE INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02304376
Desmopressin Spray · DIN 02242465
Shortage status: active shortage (reported 2026-09-08, estimated to end 2026-10-23, last updated 2026-10-02); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242465
DDAVP · DIN 00402516
Shortage status: discontinued (2021-01-29, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00402516
DDAVP · DIN 00824305
Shortage status: discontinued (2022-02-28, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00824305
DDAVP · DIN 00824143
Shortage status: discontinued (2022-05-31, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00824143
DDAVP Melt · DIN 02285010
Shortage status: discontinued (2022-03-31, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285010
DDAVP · DIN 00836362
Shortage status: discontinued (2020-07-14, reported by FERRING INC); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00836362
For Bipazen, DDAVP: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.